None
Quote | Pharnext SA (OTCMKTS:PNEXF)
Last: | $400 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $400 |
High: | $0 |
Low: | $0 |
Volume: | 16,660 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Pharnext SA (OTCMKTS:PNEXF)
PARIS, FRANCE / ACCESSWIRE / January 4, 2023 / Pharnext SA (FR001400BV89:ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the appointment of Scott Johnson a...
French biotech Pharnext ( OTC:PNEXF ) appointed Rob Quinn as CFO, effective immediately. Quinn replaces Valérie Worrall, who stepped down to pursue other interests, the company said in a Sept. 1 press release. Quinn recently served as CFO of Benevol...
Message Board Posts | Pharnext SA (OTCMKTS:PNEXF)
Subject | By | Source | When |
---|---|---|---|
PNEXF: effective Nov. 23,2022 a one for 5,000 | Renee | investorshub | 11/22/2022 2:04:01 PM |
Thanks for sharing this info with us. | Manwaring | investorshub | 03/10/2020 3:45:58 PM |
It's good to now, thanks. | Manwaring | investorshub | 02/27/2020 1:57:10 PM |
Thanks for sharing this info with us. | Manwaring | investorshub | 01/28/2020 2:56:04 PM |
What exactly do you want? | Manwaring | investorshub | 01/08/2020 2:31:57 PM |
News, Short Squeeze, Breakout and More Instantly...
Pharnext SA Company Name:
PNEXF Stock Symbol:
OTCMKTS Market:
PARIS, FRANCE / ACCESSWIRE / January 4, 2023 / Pharnext SA (FR001400BV89:ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the appointment of Scott Johnson a...
PARIS, FRANCE / ACCESSWIRE / March 31, 2021 / Pharnext SA (FR0011191287 - ALPHA) (the 'Company'), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PL...
€6 million capital raise priced at market with warrants subscribed by two existing shareholders, €5 million convertible bonds issued to European investors, European investors have also provided written indication of strong interest for the potential of additional ...